Joseph D. Khoury, MD

Department Affiliations
Chair
Stokes-Shackleford Professor 

Dr. Joseph Khoury is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. Prior to this new role, Dr. Khoury was Professor in the Division of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is recognized internationally as a leader in the field of hematopathology, in which he combines longstanding expertise in clinical diagnostics, teaching, and translational research. Dr. Khoury has authored over 300 publications, in addition to textbooks and numerous book chapters. He has received multiple awards for teaching, mentorship, research, and clinical achievements. Dr. Khoury has lectured extensively at various venues and conferences across the United States and the world, in addition to having organized multiple successful international and regional medical educational conferences. He is an active member of the College of American Pathologists, where he serves currently as Chair of the CAP Cancer Committee, which publishes CAP’s widely utilized protocols for cancer reporting. Dr. Khoury is the Chair of the Standing Editorial Board of the WHO Classification of Tumours and has contributed significantly to the 5th edition of the classification of hematolymphoid neoplasms.

Interests
Hematopathology
Cancer biomarkers
Applied computational biology, artificial intelligence, and machine learning
Cancer classification and reporting

Education and Training
BS, Biology, American University of Beirut, Beirut, Lebanon, 1993 (Cum Laude)
MD, American University of Beirut, Beirut, Lebanon, 1997
Residency, Anatomic and Clinical Pathology, Case Western Reserve University / University Hospitals of Cleveland, Cleveland, OH, 1997-2001
Fellowship, Clinical, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 -2003 
Board Certified in Anatomical and Clinical Pathology, 2002
Board Certified in Hematology, 2005
Board Certified in Medical Quality, 2014

National Activities
College of American Pathologists (CAP) Fellow, 1998 - present
International Academy of Pathology/US and Canada
American Society for Hematology
Society for Hematopathology/European Association for Hematopathology

Notable Publications
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Khoury JD, Solary E, Abla O, et al. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. PMID: 35732831

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Alaggio R, Amador C, Anagnostopoulos I, et al. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. PMID: 35732829

Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. El Hussein S, Chen P, Medeiros LJ, Wistuba II, Jaffray D, Wu J, Khoury JD. J Pathol. 2022 Jan;256(1):4-14. doi: 10.1002/path.5795. PMID: 34505705

CellSpatialGraph: Integrate hierarchical phenotyping and graph modeling to characterize spatial architecture in tumor microenvironment on digital pathology. Chen P, Aminu M, Hussein SE, Khoury JD, Wu J. Softw Impacts. 2021 Nov;10:100156. doi: 10.1016/j.simpa.2021.100156. Epub 2021 Oct 9. PMID: 36203948

Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. Chen P, El Hussein S, Xing F, Aminu M, Kannapiran A, Hazle JD, Medeiros LJ, Wistuba II, Jaffray D, Khoury JD, Wu J. Cancers (Basel). 2022 May 13;14(10):2398. doi: 10.3390/cancers14102398. PMID: 35626003

Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia. El Hussein S, Chen P, Medeiros LJ, Hazle JD, Wu J, Khoury JD. Mod Pathol. 2022 Aug;35(8):1121-1125. doi: 10.1038/s41379-022-01015-9. PMID: 35132162

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. Blood. 2022 Jul 7;140(1):58-72. doi: 10.1182/blood.2021013983. PMID: 35390143

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Blood Cancer J. 2022 Jan 11;12(1):5. doi: 10.1038/s41408-021-00603-3.  PMID: 35017466

Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Wang W, Xu J, Khoury JD, Pemmaraju N, Fang H, Miranda RN, Yin CC, Hussein SE, Jia F, Tang Z, Hu S, Konopleva M, Medeiros LJ, Wang SA. Cancers (Basel). 2022 Jul 11;14(14):3375. doi: 10.3390/cancers14143375. PMID: 35884435

Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Fang H, Khoury JD, Torres-Cabala CA, Ng SB, Xu J, El Hussein S, Hu S, Vega F, Li S, Tang Z, Tang G, Medeiros LJ, Wang W. Pathology. 2022 Jun 29:S0031-3025(22)00186-6. doi: 10.1016/j.pathol.2022.04.012. PMID: 35864006